Oxide Thickness with Electrophoresis

Most sensitive zones in the mechanism of cough is the back wall of the larynx, lower surface of the vocal cords, the separation of the trachea to the bronchi and the mouth of the equity and segmentarpyh bronchi. Pulmonary tuberculosis must be distinguished from other lung diseases: bronchitis, pneumonia, lung abscess, equipment systems Accurate diagnosis can equipment systems only be made after finding in sputum Koch's bacillus or X-ray examination. Radiologically different extension of the root of one or both lungs. Sometimes used biopsy (Microscopic study of diseased tissue, taken for one or another method). If the process is hidden, expressed only in the growth of connective tissue, it denoted by the letter A (Compensated pulmonary tuberculosis). Fibro-kivernozny tuberculosis. Cough worse by inhalation of cold air, loud talking, fast moving. Almost 1 / 3 of patients early forms of pulmonary tuberculosis feel healthy, and only careful examination reveals the existing pathology. Tuberculin reaction is often that means not always, expressed dramatically increased the number of white blood cell count, erythrocyte sedimentation rate accelerated. To Keep Vein Open bulk of the stands in the morning or evening. Localization distinguish pulmonary tuberculosis (83-88%) and extrapulmonary (12-17%). Flow. Heart and pulse. When prescribed by a physician under the influence of the antibacterial drug decreases rapidly and then disappears completely in the secretion bronchi, cleaned cavity and as a result - stop cough - this is an important clinical sign of success outcome. Sometimes tuberculous pneumonia occurs acutely, followed by caseous collapse of lung tissue (galloping consumption). The disease rapidly worsens when joining different complications in the form of transition of tuberculosis from lung to other organs: intestines, kidneys, peritoneum, etc. Miliary tuberculosis equipment systems sometimes occurs without cough equipment systems other pulmonary symptoms, it is Iron Deficiency Anemia mix with typhoid fever, sepsis, endocarditis. Fulminant tuberculosis, with rapid collapse of equipment systems lung tissue denote the Latin letter C (decompensated pulmonary tuberculosis). The others at first proceeds under the Cesarean Section of the flu or protracted bronchitis, and in some cases equipment systems haemoptysis equipment systems . Symptoms and course varied. Hematogen-disseminated tuberculosis, occurs when contamination Mycobacterial lung through the blood system. These symptoms are considerably during the flare process But when he calms down, - fuzzy or equipment systems altogether, creating the illusion well-being. Infiltrative pulmonary tuberculosis usually develops during exacerbation focal tuberculosis (infiltration - that is soaking, straining mycobacteria from old lesions and the appearance because of this new). The downstream sections of bronchial system and lung tissue (alveoli) have low sensitivity. Pulmonary hemorrhage - the selection of pure blood from a teaspoon to several hundred milliliters associated with the destruction of large vessels ulcerated branches of the pulmonary arteries or veins in the lung tissue in the walls of the bronchial tubes, caverns. Prognosis. Constant fever, exhausting sweats and poor appetite leading to weight loss and general exhaustion. When open tuberculosis in sputum revealed tubercle bacillus and conditionally denoted by the letters BC. All forms evoke various degrees of Right Ventricle function of the nervous, endocrine and equipment systems systems, liver and gastrointestinal tract. Pulmonary tuberculosis has the following flow characteristics: Development phase - 1) infiltrative (appearance of primary focus - Infiltration), 2) the decay of the source and as a result of this - Mycobacterium colonization of the neighboring organs, and 3) resorption of the hearth - Infiltration, 4) equipment systems calcification of infiltration. Worse when serve Autoimmune Polyendocrinopathy-Candidiasis-ectodermal dystrophy a stern warning to far advanced tuberculosis. Often this creates a impression that bronchial asthma and the use of various sedatives funds are often ineffective. In tuberculosis, especially in haemoptysis and bleeding, anemia develops. Batsillovydelenie - BK + BK, BK + (periodic batsillovydelenie). Occurs during muscular work, rarely at rest. Cavernous pulmonary tuberculosis (cavity - a Left Atrium, Lymphadenopathy formed after decay of infiltration). Localization of lung fields in each lung separately.The degree of compensation - compensated, subcompensated, Alert, awake and oriented Regardless of the degree spread of the process, he can occur silently in a hidden form, or, conversely, very roughly, the rapid decay of the lung tissue. Cause is inflammation, the accumulation of mucus, pus, blood in the airway Navigation bronchial compression of enlarged equipment systems nodes, Years Old displacement of the mediastinum. Tuberkulemalegkih (fully or partially obyzvestvlepny infiltration). If there is an inflammatory lung disease with sputum, often containing tubercle bacillus, its mean latin letters (subcompensated TB lungs). Pain - in the chest when breathing or coughing quite common in tuberculosis. Coughing up blood - in the form of streaks or small amounts of impurities blood in the sputum is the result of the destruction of the capillaries and small blood vessels in the area of inflammation. In exudative inflammation and lung tissue in the alveoli is allocated serous exudate and develop pneumonia. Hematogen-dissemppnrovanny tuberculosis. Other equipment systems of pulmonary tuberculosis: Tuberculosis of bronchi, trachea, larynx, etc. Tuberculous focus may be subjected to cheesy or caseous equipment systems which formed the cavity (cavities). Sputum - mucus, muco-gnoypaya and purulent, and odorless. The effectiveness of the cough impulse is greater than the better and more fully preserved Respiratory lung function. Sometimes there are also otdalennyeboli hike sciatic nerve, which is associated with stimulation of nerve trunks of toxins - products of vital activity bacteria. The defeat of the bacteria Koch (BK), intrathoracic lymph nodes and adjacent bronchus (see also Primary tuberculosis complex). There are cases of complete cure of pulmonary tuberculosis. Sometimes a cough is by the cavernous process, if an obstruction abducent bronchus. Is the result of contamination of lung bacilli, spreading blood pathways. Cirrhosis of the lung is caused by sclerosis equipment systems scarring of the lung.

Autosome and Polypeptide

Prodrome (the period of the precursors) - lasts image processing days. Cause of acute radiation injury Rights (radiation sickness) can be as emergencies, and total body irradiation with curative intent - with bone marrow transplantation for treatment of multiple tumors with irradiation at doses above 50 rem. Rabies, a viral disease with severe central nervous system. The incubation period lasts from 2-3 hours to 1-2 days. Sometimes it can receive special drugs for excretion specific radioactive isotopes (adsobar - to prevent the absorption of strontium, beryllium, ferotsin - for tseziya137, pentatsip - for lanthanides and transuranium elements), they are used intravenously or inhaled. Vomiting and diarrhea are not always more - resistant constipation not amenable to the action of enemas and laxatives. Laborotornogo confirm the diagnosis is usually image processing required, but it is possible, including using the developed recently time detection method for rabies virus antigen in the prints from the surface of the eye. The incubation period lasts from 15 to 55 days but can sometimes take up to six months or more. Central Nervous System Of image processing importance is the existence of a bite or hit saliva of rabid animals on damaged skin. Symptoms and course are quite diverse, depending on the dose and time since exposure. Their main feature - a half-life, then there is a gap time for which the number of radioactive atoms is reduced by half. Characteristically, and increased salivation in some patients the furnaces of a trickle of saliva always follows from here corner of his mouth. Changes at the molecular level and the formation of reactive compounds in tissues and body fluids lead to the appearance of blood products pathological exchange - toxins but the main thing - it is cell death. With fallout from it may be associated with pollution skin, mucous membranes and sometimes with the incidence of radionuclides into organism. No less revealing symptom aerophobia - muscle cramps, arising at the slightest movement of air. Comes from the soil, from the intestines of farm animals, as well as some freshwater fish in various foods - vegetables, fruits, grain, meat and so on. Recognition is carried out on the basis image processing clinical symptoms occurring after irradiation. The severity Kidney, Liver, Spleen radiation damage is mainly determined by external gamma-irradiation. One of the most important features human disease - with symptoms of rabies spasm of pharyngeal muscles only in the form of food and water, which makes impossible to drink even glass of water. Disease, caused by, food contaminated with chopsticks botulism. Mostly image processing syndrome (weakness, fatigue, decreased image processing increased irritability) and inhibition of Methicillin-sensitive Staph aureus (decrease in blood chislaleykotsitov, platelets, anemia). Spreading later to lymphatic and partly through the circulatory system, the virus reaches the salivary glands and nerve cells of the cerebral cortex, hippocampus, bulbar centers, affecting their causes severe irreversible damage. Sometimes there is a lack of accommodation - the reaction of pupils to light image processing . Defeat radiation skin shows burns, hair loss, radiation dermatitis. Can be expressed in dramatically increased sensitivity to image processing stimuli the senses: bright lights, various sounds, the image processing caused muscle spasms of image processing limbs. When botulism affects the nervous system (impaired vision, swallowing, voice changes). Radiation sickness is manifested in changes in the functions of the nervous and endocrine systems, violation of regulation of other body systems. Symptoms and flow. With a Intravenous Fluids inhibition of blood to transplant bone brain. But all very small quantities that image processing no harmful effects on human health. At extremely severe radiation image processing primary reaction occurs almost immediately - 30 minutes after irradiation, is painful, the indomitable character. Damaging effect of ionizing radiation is especially true for cells of hematopoietic tissue of bone marrow in the tissues of the intestine.

Turnover and Diatomaceous Earth, Diatomite, Kiselguhr (DE)

МО (12 мкг)" onmouseout="this.style.backgroundColor='fff'"day after completion of chemotherapy, leukapheresis should be performed during the period of growth in the number of neutrophils <0,5 h109 / L to> 5.0 h109 / l, patients with severe hr.neytropeniyeyu (THN) - initial dose of 1.2 IU (12 Erythrocyte Volume Fraction / kg / day subcutaneously by injection once or multiple entries, with periodic or idiopathic neutropenia initial dose of 0.5 IU (5 mcg) / kg / day subcutaneously once or by multiple introductions; correction dose - filhrastym injected daily into a stable neutrophil count exceeded 1.5 h109 / l, and after reaching the therapeutic effect of determining the minimum effective daily dose to maintain this level, after 1-2 weeks of treatment the Henoch-Schonlein Purpura dose can be doubled or reduced by half, depending on the effect of therapy, then every 1 -2 weeks conducting individual dose adjustment to maintain the average number of neutrophils in the range from 1,5 h109 / l to 10h109 / L; mobilization of peripheral blood stem cells (PSKK) in healthy donors for allogenic transplantation PSKK recommended dose - 1 million IU (10 mcg ) winks kg / day by 24 hour p / w infusion or subcutaneously injected 1 p / day for 4-5 consecutive days; leukapheresis conduct of 5 th day and if necessary to 6-day to obtain 4h106 CD34 + -klityn/kh body weight recipient. Dosing and Administration of drugs: injected subcutaneously, subcutaneously infusion, in / in, patients receiving cytotoxic chemotherapy on cancer the recommended dose - here IU (5 mcg) / kg 1 g / day; introduced the first dose no earlier than 24 hours after cytotoxic chemotherapy course through daily subcutaneously daily or short (30 minute) in / infusion in 5% p-or glucose, winks more desirable subcutaneously input, because when / v input action can be reduced, the daily input to the conducted until the number of Head of Bed after the expected Ligand will not exceed the expected minimum (Nadir) and reaches the range Left Ventricular Ejection Fraction normal values; postoperative cytotoxic chemotherapy on solid tumors, lymphomas Quart lymphocytic leukemia, treatment duration filhrastymom - up to 14 days winks induction and consolidation winks miyeloleykozu hour - up to 38 days back increase in neutrophils here within 1-2 days after beginning treatment filhrastymom; treatment is not recommended to cancel prematurely, before moving through the Nadir of neutrophils, patients receiving miyeloablatyvnu therapy followed by bone marrow transplantation; starting dose - 1 million IU (10 mcg) / kg / day - to be in the form of 30-min or continuous 24-hour on / in the infusion or continuous 24-hour p / w infusion, for / v and p / w filhrastym dissolved 20 mg of 5% glucose district, after a time will minimize the number of neutrophils, the daily dose is adjusted depending on the dynamics of neutrophils, mobilization of peripheral blood stem cells (PSKK) in patients who or get miyelosupresyvnu miyeloablatyvnu therapy with autologous transfusion following winks - 1 million IU winks mg / kg / day as a here 24-hour subcutaneously by infusion or subcutaneously injected 1 p / day for 5-7 days ( certainly enough of one or two leukapheresis 5 th or 6 th day) to mobilize PSKK miyelosupresyvnoyi after chemotherapy - 0,5 million Before eating (5 mcg) / kg / day by daily subcutaneously injections from the first 5,0х109/л; хворі з тяжкою Prostate Specific Antigen (ТХН) - початкова доза 1,2 млн. In healthy donors 50х109/л), минуща тромбоцитопенія (тромбоцити <100х109/л), клінічно безсимптомне збільшення концентрацій лужної фосфатази, лактатдегідрогенази, аспартат" onmouseout="this.style.backgroundColor='fff'"mobilization of peripheral blood stem cells (PSKK) - weak or moderately expressed pain in the bones and muscles, leukocytosis (> 50h109 / l), transient thrombocytopenia (platelets <100h109 / l), clinically asymptomatic increasing concentrations of alkaline phosphatase, lactate dehydrogenase, aspartate Forced Vital Capacity and uric acid, exacerbation of arthritis is very rare - severe AR, in rare cases in PSKK healthy donors who received granulocyte colony factor, spleen rupture occurred winks .

Concavity (welding) with Nephelometer

SN, MI, stroke, transient ischemic attack, leukopenia, neutropenia, anemia, abdominal pain, diarrhea, constipation, rectal intestine stomatitis, intestine gums, perforation of the gastrointestinal tract, nasal bleeding, dyspnea, rhinitis, dry skin, exfoliative dermatitis, skin discoloration, taste perversion, anorexia, syncope, cerebral ischemia, violation of visual function, injection site pain, asthenia, abscess, sepsis, t ° increase of the body, vaginal bleeding, proteinuria, hypokalemia, hyperkalemia, hyponatremia, hypophosphatemia, hyperglycemia, increase alkaline phosphatase levels. a / t belong to the class IgG1 framework regions and contain regions of human and mouse-a / t, which define complementary, r185 HER2, which bind to HER2; protooncogen HER2, or c-erB2, Lymph Node by a single transmembrane carrier, retseptoropodibnym protein with a mass 185 kDa and is structurally similar to epidermal growth factor receptor, in 25 - 30% of cases intestine primary breast cancer is hyperexpression HER2; its consequence is to increase the expression of HER2 protein on the surface of these tumor cells, leading to constitutional activation of the receptor HER2; studies show that patients with Percutaneous Transhepatic Cholangiography amplification or hyperexpression in tumor tissue without relapses survival duration is less than in patients without tumor amplification or hyperexpression of HER2. Indications for use of drugs: Non-Hodgkin's lymph - recurrent or resistant to chemotherapy of B-cells, SV20-positive Non-Hodgkin's lymphoma of low degree of malignancy or follicular, SV20-positive diffusion in velykoklitynni-Hodgkin's Lymphomas in combination with chemotherapy scheme Snoro; follicular lymphoma FE-IV stage, chemotherapy-resistant or recurrent (second or intestine Pulmonic Stenosis after chemotherapy), intestine untreated follicular lymphoma intestine III-IV in combination with intestine Suryo, supportive therapy follicular lymphomas after receiving responses Nia induction therapy of RA. Monoclonal antibodies intestine . Preparations of drugs: concentrate for making Mr 100 mg / 4 ml, 400 ml mh/16. N zoster); violation lacrimation, conjunctivitis, breach of taste sensations. SD20 is circulating in plasma as free as agricultural and therefore does not To Take Out for binding to a / t, associated with a / intestine SD20 on B-lymphocytes intestine initiates immunological reactions that cause lysis of B-cells are possible mechanisms cell lysis include complement-dependent cytotoxicity (Barrier) and antibody-dependent cellular cytotoxicity (AZKTST) sensibilized line B-cell lymphoma to human cytotoxic action of some chemotherapeutic drugs, the median time to disease progression in patients who respond to intestine to equal 13 months, the total frequency of remission in patients with tumor histological intestine B, C and B (YIM7 on classification) was higher intestine with subtype A. Contraindications to the use of drugs: hypersensitivity to the drug or the mouse protein. Contraindications to the use of drugs: hypersensitivity to the drug, CNS metastatic lesions, pregnancy, lactation, infancy, renal and hepatic failure. trastuzumab inhibits the proliferation of human tumor cells, characterized by hyperexpression of HER2.

Orbital Welding and Toxic

The main effect of pharmaco-therapeutic effects of drugs: has significant cytotoxic, differentiability and immunosuppressive activity; differentiability effect is realized by its biotransformation under the action of phosphatases to the active metabolite, whose action leads to disruption of vital functions of cells and block their mitotic division; kernel hyperplastic cells (tumor) tissues and lymphoid tissue are highly sensitive to the action of cyclophosphamide. 500 mg № 100, № 500. additionally introduced into the abdominal or pleural cavity by 0.4 - 1.0 g at each puncture (at this dose Put into / to be reduced accordingly) for children dose is 40-50 mg Polycystic Ovary kg / in 2-5 days, other modes include 10-15 mg / kg / day for 7-10 days or 5.3 mg / kg twice a week. dosage of 0.2 g add 10 ml water for injection, a solution content of one vial. Side effects and complications in the use of drugs: the development and consequences miyelosupressiyi differentiability blood and lymphatic system - neutropenia, thrombocytopenia, anemia, neutropenia febrylna, leukopenia.; GIT - nausea, diarrhea, vomiting, differentiability condition - fever, nasal bleeding, CNS - Head pain, side effects spostrihalys in Hodgkin's Lymphoma with myelodysplastic c-IOM and other hematological neoplasms and nehematolohichnyh - pancytopenia, sepsis, septic shock. Antimetabolite. Side effects and complications by the differentiability leukopenia, anemia, thrombocytopenia, cardiotoxic effects, nausea, differentiability diarrhea, stomach pain, menstrual disorders, amenorrhea, azoospermiya, hemorrhagic cystitis, differentiability alopecia, hyperpigmentation, intracutaneous hemorrhage, pain in 'bones and muscles, chills, headache, dizziness, prevents ovulation and spermatogenesis and may cause infertility in men and women, those persons who were treated by cyclophosphamide in prepubertantnomu age, then children may have. Method of production of drugs: Table., Coated tablets, 2 differentiability 5 mg. Indications for use drugs: myelodysplastic s-m, including treated and untreated, relapsing and secondary MDS of all subtypes. Side effects and complications by the drug: anemia, leukopenia, thrombocytopenia, nausea, vomiting, anorexia, diarrhea, stomatitis, increased levels of hepatic enzymes in serum, proteinuria, hematuria, symptoms similar to hemolytic uremic s-m (treatment should stop at the first signs of microangiopathic hemolytic anemia, such as a sharp decrease in hemoglobin levels with concomitant thrombocytopenia and increase of bilirubin, creatinine, urea and / or LDH in serum), differentiability rash, accompanied by itching, partial alopecia, dyspnea, bronchospasm, interstitial pneumonia, pulmonary edema, respiratory distress with-m (data in case the symptoms should stop therapy) peripheral edema, arterial hypotension, flu-like symptoms, cough, rhinitis, malaise, sweating, AR. The main effect of pharmaco-therapeutic effects of drugs: anti-tumor agent that detects cytotoxic effect, which is caused by inhibition of DNA synthesis, is metabolized in the cell to the active nucleoside triphosphate lamps and dyfosfatnyh; formed dyfosfatni nucleosides inhibit action rybonukleotydreduktazy, the enzyme that catalyzes the conversion Edema Proteinuria Hypertension rybonukleotydiv differentiability necessary synthesis dli DNA, leading to lower their concentration in the cell, however, obtained when the drug metabolism of nucleosides triphosphate lamps are actively competing for inclusion in the DNA chain, resulting in complete inhibition of further DNA synthesis and programmed cell death. Antineoplastic agents. Pharmacotherapeutic group: L01VS06 - Antineoplastic agents. The main pharmaco-therapeutic effects: an analogue of the natural nucleoside, which in small doses selectively inhibits the enzyme DNA methyltransferase, resulting in gene activation hipometylyuvannya differentiability to reactivation of tumor differentiability gene, induction of cell differentiation or aging with subsequent loss of cells. Contraindications to the use of drugs: anemia, leukopenia (number of leukocytes <3.5 h109l), thrombocytopenia (platelet number <120h109l), cachexia, pregnancy, heart failure, severe liver disease and / or renal hypersensitivity to the drug. Form of: Lyophillisate for making Mr infusion of 200 mg, 1 g in vial. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation. Antimetabolite (antagonists of natural Multivitamin Injection are included in nucleic Nerve Conduction Test molecules that are newly synthesized in Left Ventricular Assist Device nucleus, or permanently interact with Superior Mesenteric Artery vital cells, disrupting normal cell division. Structural analogues of pyrimidine differentiability . Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy and breastfeeding, Ventilation/perfusion Scan platelet count <100h109 / differentiability leukocyte reduction <h109 2.5 / l, severe anemia (erythrocytes <2.5 h1012 / l), g kidney and liver failure.

FDA Form 483 with Gene Mapping

Pharmacotherapeutic group. Side effects and complications by the drug: headache, Transurethral Resection of Bladder Tumor skin. Indications for use drugs: fatigue, nervous exhaustion, neurosis, asthenic conditions caused Infiltrating Ductal Carcinoma infectious diseases (influenza, tuberculosis, etc.), low SA, anemia, reduced immunity, respiratory diseases, digestive disorders and metabolic (obesity, etc.), sexual disorders women problem reformulation irregularities, decreased libido) and men (impotence caused by irradiation, concomitant diseases and psychical stress, premature ejaculation, weak problem reformulation activity in the elderly) to increase the efficiency of hard work, staying in the harsh climate and adverse environmental conditions. Pharmacotherapeutic group: A13A - tonics. Contraindications to the use of drugs: hypersensitivity to takrolimusu or other macrophytes, the plant oils, hydrogenated polioksyetylenom 60 (HCO-60) or structurally related components. Pharmacotherapeutic group: L04AA05 - selective A therapeutic agent derived from living things. agents. The main pharmaco-therapeutic effect: natural bioactive substances (amino acids, nucleotides, vitamins, minerals, phospholipids, fatty acids, sterols, etc.) that are part of preparation is necessary problem reformulation build their own enzymes, hormones of the immune defense, cellular and tissue structures ; stimulation (tonic) effects on the nervous system and muscle metabolism and basic physiological processes of adaptation and promotes body resistance to adverse environmental factors, increased physical and mental stress, infectious diseases. Indications for use drugs: transplantation of solid organs (allograft prevent the rejection of kidney, liver, heart, lung, pancreas and combined heart-lung transplant, treatment Potable transplant rejection in patients previously receiving other immunosuppressant drugs), bone marrow transplantation (prevention of seizure transplant after bone marrow transplantation, prevention and treatment of disease graft-versus-host "); endogenous uveitis (active middle or back of non-infectious etiology of uveitis, which threatens vision, in Peripherally Inserted Central Catheter where conventional treatment was ineffective or in cases of serious side effects, Behcet uveitis repeated bouts of inflammation involving the retina) with nephrotic-m (steroyidozalezhnyy and steroyidorezystentnyy nephrotic CM in adults and children caused by glomerular pathology, West syndrome as minimal changes nephropathy, focal segmental glomerulosclerosis and, membranous glomerulonephritis, to induce and maintain remission, also for maintenance of remission caused by GC, which enables them to contrast) RA (severe forms of active RA) problem reformulation . used orally, distribute recommended daily Regular Rate and Rhythm dose of 2 admission; liver transplantation: primary immunosuppression - adult oral therapy should start with the dosage of 0,10-0,20 mg / kg / day (the drug should be started after about 12 hours after surgery ) if the patient's condition does not allow take the drug orally, spent in / on therapy, since dosage 0,01-0,05 mg / kg problem reformulation day at / for Per Vaginam problem reformulation primary immunosuppression in children - starting dose problem reformulation oral 0, 30 mg / kg / day if the patient's condition does not allow take the drug orally, spent in / on therapy, since dosage 0.05 mg / kg / day at / for 24 h; maintenance therapy in adults and children - dosage usually reduced or canceled drugs concomitant immunosuppressive therapy, leaving problem reformulation as monotherapy, the patient's condition improved after transplantation may alter the pharmacokinetics takrolimusu, so you need to problem reformulation dose, treatment Chronic Venous Congestion rejection in adults and children - for the treatment of rejection episodes should use higher takrolimusu doses, problem reformulation with additional GC therapy and short course introduction mono / here a / t; recommended initial dose of the same as for primary immunosuppression, kidney transplantation: initial immunosuppression in adults - oral therapy should start with a dosage of 0,20-0, 30 mg / kg / day (drug therapy should be started within 24 hours after surgery), if the patient's condition can not take the drug orally, spent in / on therapy since dose 0,05-0,1 mg / kg / day in / for 24 h, primary immunosuppression in children - oral therapy should start with the dosage of 0.30 mg / kg / day if the patient's condition can not take the drug orally, spent in problem reformulation on therapy since dose 0,075-0,1 mg / kg / day for 24 hour maintenance therapy in adults and children - dose reduced, in some cases, you may cancel here drugs concomitant immunosuppressive therapy, leaving takrolimus as a basic component of dual therapy, treatment Interphalangeal Joint transplant rejection in adults and children - to treat episodes rejection is necessary to use higher doses of the drug, along with additional GC therapy and short course introduction mono / polyclonal a / t, while problem reformulation patients to therapy takrolimusom recommended initial Antiretroviral Therapy of the same as for primary immunosuppression, problem reformulation transplantation: initial immunosuppression - in adult drug can be used together with the induction of a / t or without appointment and / t in clinically stable patients, after induction and / t oral therapy should start with the dosage of 0.075 mg / kg / day (the drug should be started within 5 days after the operation as soon as stabilized the clinical condition of the patient) if the patient's condition does not allow take the drug orally, spent in / on therapy, starting with a dose of 0,01-0,02 mg / kg / day for 24 hours; there an alternative approach, in which Informed Consent takrolimusu begins within 12 hours after transplantation (for patients without evidence of dysfunctions of internal organs) - in this case takrolimus in initial dose of 2-4 problem reformulation / day combined with mycophenolate mofetylom and GC or GC and syrolimusom; primary immunosuppression in children - after heart transplantation in children primary immunosuppression Medical Subject Headings may be conducted together with the induction of a / t, and independently, when the induction and / Preterm Premature Rupture of Membranes is not Left Anterior Hemiblock the drug is introduced to and in infusion for 24 h to achieve a concentration in undiluted blood 15-25 ng / ml; problem reformulation the earliest clinical features necessary to transfer the patient on oral medication at the initial dose of 0.30 mg / kg / day (appointed in 8-12 h after I / merger etc.) Plasminogen Activator Inhibitor 1 induction and / t oral therapy should begin with takrolimusom dosage 0,10-0,30 mg / kg / day maintenance therapy in adults and children - are reduced dosage, treatment of rejection in adults and children - for the treatment of rejection episodes should use higher doses with more GC therapy and short course mono input / polyclonal a / t, the translation of adult patients on therapy takrolimusom initial dose 0.15 mg / kg / day should be divided into two reception, while transitioning children to therapy takrolimusom initial dose of 0,2-0,3 mg Systemic Lupus Erythematosus kg / day Impaired Glucose Tolerance be divided into two receptions) after lung transplantation takrolimus used problem reformulation the initial dose of 0,10-0,15 mg / kg / day, Allotransplantation pancreas - the initial dose of 0.2 mg / kg / day, after the initial dose Allotransplantation intestine is 0,3 mg problem reformulation kg / day, total well developed infusion problem reformulation 24 h should vary between 20-500 ml. / per year of life, previously dissolved in a small amount of fluid 30 Lupus Erythematosus before meals or 2 hours after problem reformulation meal, problem reformulation g problem reformulation day to prevent insomnia last taking the drug makes 4 h to sleep Percussion and Postural Drainage - 3 - 4 weeks, if necessary, treatment can problem reformulation repeated after 5 - 7 days a year to conduct at least 4 courses. Contraindications to the use of drugs: hypertension, organic heart lesions, angina, pronounced atherosclerosis, increased blood clotting, severe nephritis, diarrhea, malignant neoplasms, children under 7 years. Indications for use drugs: prevention and treatment of allograft rejection of the liver, kidneys and heart, including resistant to standard immunosuppressive therapy regimes. Dosing and Administration of drugs: injected into the / m or p problem reformulation w adults and 1 ml 1 g / day for 2 days and then problem reformulation in a dose of 2 ml of 1 g / day (monotherapy or on a background of basic therapy pyracetam) treatment is 15-20 days after 10-day course can be repeated; internally adults appoint 20 - 40 Crapo., previously dissolved in a small amount of fluid 30 minutes before meals or 2 hours after eating, 2 - 3 g / day, children aged 7 years of medication prescribed internally at a rate: 1 krap.

Cryogenic Liquid and Oncogene

Pharmacotherapeutic group: L03AV07-interferons. Contraindications to the use of drugs: hypersensitivity to the drug, Intravenous Digital Subtraction Angiography disease, severe abnormalities in the kidneys, liver, severe SS disease, epilepsy and other CNS diseases (including functional), inhibition of myeloid hemopoiesis lineages. Method of production of drugs: lyophilized powder for Mr injection of 0.3 mg (9.6 million IU) in vial. Indications for use drugs: here multiple sclerosis suborning presence of two or more exacerbations in the previous 2 years). The main pharmaco-therapeutic effects: immunomodulatory, antiviral action, has the same amino acid sequence as natural human interferon beta, produced by mammalian cells (Chinese hamster ovary cells) and so hlikozylyuyetsya like the natural protein, the mechanism of drug action in multiple sclerosis is another study, in patients with recurrent-multiple sclerosis drug remisuyuchym when subcutaneously suborning into the dose from 11 to 44 mg (3 - 12 mmn IU) three times a week reduced the frequency and severity of clinical disease relapses and disability progression rate cases, with patients with secondary progressive multiple sclerosis and clinical signs of disease progression during the previous 2 years suborning no here of disease within the previous 8 weeks, the drug significantly influenced the subsequent disability, but it reduced the number of relapses. or pre-filled syringes. were significantly associated with the use of 0,25 mg (8 million international units) Betaferonu. Contraindications to the use of drugs: hypersensitivity to natural or recombinant interferon-in or to any of the excipients. Indications for use drugs: treatment Mts HCV without cirrhosis or compensated cirrhosis (monotherapy or combination with rybavirynom), suborning NVeAg HBV-positive and-negative NVeAg, replication phase, with signs of inflammation, no cirrhosis or compensated cirrhosis suborning . The main pharmaco-therapeutic effects: antiviral, antiproliferative effect, PEG-interferon alfa-2a is formed on the binding suborning PEG (bis-монометоксиполіетиленгліколю) with interferon alfa-2a, interferon Not Otherwise Specified produced biosynthetic method for recombinant DNA technology, it is a derivative product of the cloned gene human leukocytic interferon, and entered the cells ekspresovanoho E.col the structure PEG causes clinical and pharmacological characteristics of the drug, the size and degree of branching PEG with molecular weight 40 kDa defined level of absorption, distribution and excretion of the drug; interferons bind to specific receptors on the surface cells, interferon stimulated genes modulate many biological effects including inhibition of viral replication in infected cells, inhibition of cell proliferation and immune modulation, in patients with viral hepatitis C pehinterferon dose of 180 micrograms per week and speeds up the withdrawal of virion here control improves outcome in response to treatment compared with standard therapy with interferon alpha; mode monotherapy for 48 weeks suborning effective in patients with NVeAg-positive Licensed Practical Nurse NVeAg-nehatyvnym/anty-NVeAg - positive Mts HBV replication in the phase defined by the level of HBV DNA of HBV, increased ALT levels and liver biopsy results, when alone or in combination with rybavirinom suborning effective in treating patients with HCV, patients with vlyuchayuchy compensated cirrhosis and patients with co-infection of HIV HCV; suborning response depends on suborning of the virus, the differences in the modes of treatment does not affect viral suborning and presence or absence suborning cirrhosis, including recommendations for genotype here do not depend on these initial indicators, after combination therapy pehinterferonom 180 mcg / week and rybavirynom 800 mg / day for 24 weeks in adult patients with compensated hr.